Effects of selective serotonin reuptake inhibitors on platelet function: Mechanisms, clinical outcomes and implications for use in elderly patients

Drugs and Aging

Volumn 28, Issue 5, 2011, Pages 345-367

  De Abajo, Francisco J ^a,b  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Antidepressants; Depression; Elderly; Haemorrhage; Platelets; Serotonin uptake inhibitors

Indexed keywords

CLOMIPRAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

AGITATION; ASIA; BACTERIAL GENE; BLEEDING TIME; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CHROMOSOME 17; CLINICAL ASSESSMENT; CLINICAL FEATURE; DEPRESSION; DIZZINESS; DOWN REGULATION; DROWSINESS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HISTORY; HUMAN; MAJOR DEPRESSION; MENTAL PATIENT; NERVE CELL; PEPTIC ULCER; POSTMENOPAUSE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RISK FACTOR; SEROTONIN UPTAKE; SIDE EFFECT; SLEEP DISORDER; SWEATING; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

AGED; BLOOD PLATELETS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PROGNOSIS; SEROTONIN UPTAKE INHIBITORS;

EID: 79955678784     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11589340-000000000-00000     Document Type: Review

References (146)

1. Lynnes JM, Caine ED, King DA, et al. Psychiatric disorders in older primary care patients. J Gen Intern Med 1999; 14: 249-54 (Pubitemid 29196428)
2. Hybels CF, Blazer DG. Epidemiology of late-life mental disorders. Clin Geriatr Med 2003; 19: 663-96 (Pubitemid 37466819)
3. Unutzer J. Late-life depression. N Engl J Med 2006; 357: 2269-76 (Pubitemid 350190757)
4. Unutzer J, Katon W, Callahan CM, et al. Depression treatment in a sample of 1,801 depressed older adults in primary care. J Am Geriatr Soc 2003; 51: 505-14 (Pubitemid 36457349)
5. Stone MB, Jones ML. Clinical review: Relationship between antidepressant drugs and suicidality in adults [online]. Available from URL: Http://www.fda.gov/ohrms/dock ets/ac/06/briefing/2006-4272b1-01-FDA.pdf [Accessed 2011 Feb 10]
6. Draper B, Berman K. Tolerability of selective serotonin reuptake inhibitors: Issues relevant to the elderly. Drugs Aging 2008; 25: 501-19 (Pubitemid 351812258)
7. Cheeta S, Schifano F, Oyfeso A, et al. Antidepressantrelated deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry 2004; 184: 41-7 (Pubitemid 38085213)
8. Harman JS, EdlundMJ, Fortney JC. Trends in antidepressant utilization from 2001 to 2004. Psychiatr Serv 2009; 60: 611-6
9. Newman SC, Schopflocher D. Trends in antidepressant prescriptions among the elderly in Alberta during 1997 to 2004. Can J Psychiatry 2008; 53: 704-7
10. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med 2009; 60: 355-66
11. Lingjarde O. Blood platelets as a model system for studying serotonergic dysfunction and effects of antidepressants. Pharmacol Toxicol 1990; 66 Suppl. 3: 61-8
12. Lesch KP, Wolozin BL, Murphy DL, et al. Primary structure of the human platelet serotonin uptake site: Identity with the brain serotonin transporter. J Neurochem 1993; 60: 2319-22 (Pubitemid 23148809)
13. Serebruany VL, O'Connor CM, Krishnan RR, et al. Hypothesis: Antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding. J Cardiovasc Pharmacol Ther 2005; 10: 163-4 (Pubitemid 41376973)
14. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37: 12-6 (Pubitemid 26021814)
15. Gerretsen P, Pollock BG. Pharmacogenetics and the serotonin transporter in late-life depression. Expert Opin Drug Metab Toxicol 2008; 4: 1465-78
16. Luddington NS, Madadapu A, Husk M, et al. Clinical implications of genetic variation in the serotonin transporter promoter region: A review. J Clin Psychiatry 2009; 11: 93-102
17. Lotrich FE, Pollock BG, Kirshner M, et al. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci 2008; 33: 123-30 (Pubitemid 351441382)
18. Galan AM, Lopez-Vilchez I, Diaz-Ricart M, et al. Serotonergic mechanisms enhance platelet-mediated thrombogenicity. Thromb Haemost 2009; 102: 511-9
19. Malinin AI, Ong S, Makarov LM, et al. Platelet inhibition beyond conventional antiplatelet agents: Expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int J Clin Pract 2006; 60: 993-1002 (Pubitemid 44096587)
20. Maurer-Spurej E. Serotonin reuptake inhibitors and cardiovascular diseases: A platelet connection. Cell Mol Life Sci 2005; 62: 159-70 (Pubitemid 40193040)
21. Markovitz JH, Shuster JL, Chitwood WS, et al. Platelet activation in depression and effects of sertraline treatment: An open-label study. Am J Psychiatry 2000; 157: 1006-8 (Pubitemid 30412355)
22. Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine: Preliminary findings. Arch Gen Psychiatry 2000; 57: 875-82
23. Shimbo D, Child J, Davidson K, et al. Exaggerated serotonin- mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol 2002; 89: 331-3 (Pubitemid 34113797)
24. Whyte EM, Pollock BG, Wagner WR, et al. Influence of serotonin- transporter-linked promoter region polymorphism on platelet activation in geriatric depression.AmJ Psychiatry 2001; 158: 2074-6 (Pubitemid 33104120)
25. Dale GL. Coated-platelets: An emerging component of the procoagulant response. J Thromb Haemost 2005; 3: 2185-92 (Pubitemid 41727196)
26. Prodan CI, Joseph PM, Vincent AS, et al. Coated-platelet levels are influenced by smoking, aspirin and selective serotonin reuptake inhibitors. J Thromb Haemost 2007; 5: 2149-51 (Pubitemid 47450036)
27. Wagner A, Montero D, Martensson B, et al. Effects of fluoxetine treatment of platelet 3H-imipramine binding, 5-HT uptake and 5-HT content in major depressive disorder. J Affect Dis 1990; 20: 101-13 (Pubitemid 20316952)
28. Hergovich N, Aigner M, Eichler HG, et al. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68: 435-42
29. Javors MA, Houston JP, Tekell JL, et al. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int J Neuropsychopharmacol 2000; 3: 229-35
30. Martensson B, Wagner A, Beck O, et al. Effects of clomipramine treatment on cerebrospinal fluid monoamine metabolites and platelet 3H-imipramine binding and serotonin uptake and concentration in major depressive disorder. Acta Psychiatr Scand 1991; 83: 125-33
31. Pigott TA, L'Hereux F, Rubenstein CS, et al. A doubleblind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12: 156-62
32. Mück-Seler D, Jakovjevic M, Deanovic Z. Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients. J Affect Dis 1991; 23: 157-64
33. Narayan M, Anderson G, Cellar J, et al. Serotonin transporter- blocking properties of nefazodone assessed by measurement of platelet serotonin. J Clin Psychopharmacol 1998; 18: 67-71 (Pubitemid 28045637)
34. Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340: 249-58 (Pubitemid 28022649)
35. Berk M, Jacobson BF, Hurly E. Fluoxetine and hemostatic function: A pilot study. J Clin Psychiatry 1995; 56: 14-6
36. Alderman CP, Moritz CK, Ben-Tovim DL. Abnormal platelet aggregation associated with fluoxetine therapy. Ann Pharmacother 1992; 26: 1517-9
37. Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007; 9: 47-59 (Pubitemid 46607130)
38. Abdelmalik N, Ruhé HG, Barwari K, et al. Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. J Thromb Haemost 2008; 6: 2168-74
39. Ruhe HG, Booij J, Weert HC, et al. Evidence why doseescalation of paroxetine in major depressive disorder is not effective: A 6-week, randomized-controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 2009; 34: 999-1010
40. Hougardy DM, Egberts TC, van der Graaf F, et al. Serotonin transporter polymorphism and bleeding time during SSRI therapy. Br J Clin Pharmacol 2008; 65: 761-6 (Pubitemid 351535089)
41. Humphries JE, Wheby MS, VandenBerg SR. Fluoxetine and the bleeding time. Arch Pathol Lab Med 1990; 114: 727-8 (Pubitemid 20207055)
42. Yaryura-Tobias JA, Kirschen H, Ninan P, et al. Fluoxetine and bleeding in obsessive-compulsive disorder [letter]. Am J Psychiatry 1991; 148: 949
43. Ottervanger JP, Stricker BHCH, Huls J, et al. Bleeding attributed to the intake of paroxetine. Am J Psychiatry 1994; 151: 781-2
44. Leung M, Shore R. Fluvoxamine-associated bleeding. Can J Psychiatry 1996; 41: 604-5
45. Calhoun JW, Calhoun DD. Prolonged bleeding time in a patient treated with sertraline [letter]. Am J Psychiatry 1996; 153: 443 (Pubitemid 26074730)
46. Khon S, Labbate LA. Venlafaxine and ecchymosis [letter]. Can J Psychiatry 1997; 42: 91
47. Balhara Y, Sagar R, Varghese ST. Bleeding gums: duloxetine may be the cause. J Postgrad Med 2007; 53: 44-5 (Pubitemid 46197709)
48. De Abajo FJ, Montero D, García Rodríguez LA, et al. Antidepressants and risk of upper gastrointestinal bleeding. Pharmacol Toxicol 2006; 98: 304-10
49. De Abajo FJ, García Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: Population based case-control study. BMJ 1999; 319: 1106-9 (Pubitemid 29494721)
50. Dunn NR, Pearce GL, Shakir SAW. SSRIs are not more likely than other drugs to cause such bleeding. BMJ 2000; 320: 1405-6
51. Van Walraven C, Mamdami MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: Retrospective cohort study. BMJ 2001; 323: 1-6
52. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: A population-based cohort study. Arch Intern Med 2003; 165: 59-64 (Pubitemid 36091601)
53. Tata LJ, Fortun PJ, Hubbard RB, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 2005; 22: 175-81 (Pubitemid 41153059)
54. Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with acute gastrointestinal hemorrhage: A multicentre retrospective analysis. Aliment Pharmacol Ther 2006; 23: 937-44
55. Opatrny L, Delaney JA, Suissa S. Gastrointestinal bleed risk with the use of selective serotonin receptor antagonists: A new look. Abstracts of the 23rd ICPE. Pharmacoepidemiol Drug Saf 2007; 16: S1-274
56. Helin-Salmivaara A, Huttunen T, Grönroos JM, et al. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: A case-control study in the general population. Eur J Clin Pharmacol 2007; 63: 403-8 (Pubitemid 46399132)
57. Lewis JD, Strom BL, Localio AR, et al. Moderate to high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol Drug Saf 2008; 17: 328-35 (Pubitemid 351566348)
58. Vidal X, Ibañez L, Vendrell L, et al., on behalf of the Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: A case-control study. Drug Saf 2008; 31: 159-68
59. De Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: Interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65: 795-803 (Pubitemid 351957705)
60. Barbui C, Andretta M, De Vitis G, et al. Antidepressant drug prescription and risk of abnormal bleeding: A casecontrol study. J Clin Psychopharmacol 2009; 29: 33-8
61. Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009; 104: 1475-82
62. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, et al. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2009; 7: 1314-21
63. Verdel BM, Souverein PC, Meenks SD, et al. Use of serotonergic drugs and the risk of bleeding. Clin Pharmacol Ther 2011; 89: 89-96
64. Tanaka A, Takahira Y, Izumi N, et al. Aggravation by selective serotonin re-uptake inhibitors (SSRIs) of antral lesions induced by indomethacin in rats: Effects of antisecretory and mucosal protective drugs [abstract]. Gastroenterology 2005: M2063
65. Yamaguchi T, Hidaka N, Suemaru K, et al. The coadministration of paroxetine and low-dose aspirin synergistically enhances gastric ulcerogenic risk in rats. Biol Pharm Bull 2008; 31: 1371-5 (Pubitemid 351930649)
66. Yamamoto T, Abe K, Hattori K, et al. High prevalence of gastroduodenal mucosa injury in patients taking selective serotonin reuptake inhibitors [letter]. Digestive Endoscopy 2010; 22: 77
67. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, et al. There is an association between selective serotonin reuptake inhibitor use and uncomplicated peptic ulcers: A population- based case-control study. Aliment Pharmacol Ther 2010; 32: 1383-91
68. Gutthann SP, García Rodríguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18-24 (Pubitemid 27014216)
69. Hernández-Díaz S, García Rodríguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: Review of epidemiologic studies. J Clin Epidemiol 2002; 55: 157-63 (Pubitemid 34051529)
70. Movig KLL, Janssen MWHE, Malefijt JW, et al. Relationship of serotoninergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch Intern Med 2003; 163: 2354-8 (Pubitemid 37310197)
71. Andreasen JJ, Riis A, Hjortdal VE, et al. Effect of selective serotonin reuptake inhibitors on requirements for allogeneic red blood transfusion following coronary artery bypass surgery. Am J Cardiovasc Drugs 2006; 6: 243-50 (Pubitemid 44285133)
72. Salkeld E, Ferris LE, Juurlink DN. The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants. J Clin Psychopharmacol 2008; 28: 230-4 (Pubitemid 351417131)
73. Kim DH, Daskalakis C, Whellan DJ, et al. Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting. Am J Cardiol 2009; 103: 1391-5
74. Xiong GL, Jiang W, Clare RM, et al. Safety of selective serotonin reuptake inhibitor use prior to coronary artery bypass grafting. Clin Cardiol 2010; 33: E94-8
75. Gärtner R, Cronin-Fenton D, Hundborg HH, et al. Use of selective serotonin reuptake inhibitors and risk of reoperation due to post-surgical bleeding in breast cance patients: A Danish population-based cohort study. BMC Surg 2010; 10: 3
76. Van Haelst IM, Egberts TC, Doodeman HJ, et al. Use of serotonergic antidepressants and bleeding risk in orthopedic patients. Anesthesiology 2010; 112: 631-6
77. Ware JA, Coller BS. Platelet morphology, biochemistry, and function. In: Beutler E, Lichtman MA, Coller BS, et al., editors. William's hematology. 5th ed. New York: McGraw-Hill, 1995: 1161-93
78. De Abajo FJ, Jick H, Derby L, et al. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol 2000; 50: 43-7 (Pubitemid 30416970)
79. Bak S, Tsiropoulos I, Kjaersgaad JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: A population-based case-control study. Stroke 2002; 33: 1465-73 (Pubitemid 34619941)
80. Kharofa J, Sekar P, Haverbusch M, et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke 2007; 38: 3049-51 (Pubitemid 350035702)
81. Chen Y, Guo JJ, Patel NC. Hemorrhagic stroke associated with antidepressant use in patients with depression: does degree of serotonin reuptake inhibition matter? Pharmacoepidemiol Drug Saf 2009; 18: 196-202
82. Smoller JW, Allison M, Cochrane BB, et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women'sHealth Initiative study. Arch Intern Med 2009; 169: 2128-39
83. Kurdyak PA, Juurlink DN, Kopp A, et al. Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol 2005 Dec; 25 (6): 561-4 (Pubitemid 41669050)
84. Schalekamp T, Klungel OH, Souverein PC, et al. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008; 168: 180-5 (Pubitemid 351185885)
85. Wallerstedt SM, Gleerup H, Sundström A, et al. Risk of clinically relevant bleeding in warfarin-treated patients: Influence of SSRI treatment. Pharmacoepidemiol Drug Saf 2009; 18: 412-6
86. Hauta-Aho M, Tirkkonen T, Vahlberg T, et al. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med 2009; 41: 619-28
87. Layton D, Clark DWJ, Pearce GL, et al. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 2001; 57: 167-76 (Pubitemid 32449139)
88. Meijer WE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164: 2367-70 (Pubitemid 39532249)
89. Ziegelstein RC, Meuchel J, Kim TJ, et al. Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med 2007; 120: 525-30 (Pubitemid 46764624)
90. Dentali F, Douketis JD, Lim W, et al. Combined aspirin: Oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease - a meta-analysis of randomized trials. Arch Intern Med 2007; 167: 117-24 (Pubitemid 46148058)
91. Delaney JA, Opatrny L, Brophy JM, et al. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347-51 (Pubitemid 47339530)
92. Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med 2003; 65: 201-10 (Pubitemid 36359331)
93. Glassman AH. Depression and cardiovascular comorbidity. Dialogues Clin Neurosci 2007; 9: 9-17 (Pubitemid 46607127)
94. Salaycik KJ, Kelly-Hayes M, Beiser A, et al. Depressive symptoms and risk of stroke: The Framingham Study. Stroke 2007; 38: 16-21 (Pubitemid 46035600)
95. O'Donnell MJ, Xavier D, Liu L, et al., INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 2010; 376: 112-23
96. Bonnet F, Irving K, Terra JL, et al. Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease. Atherosclerosis 2005; 178: 339-44 (Pubitemid 40193449)
97. Bruce EC, Musselman DL. Depression, alterations in platelet function, and ischemic heart disease. Psychosom Med 2005; 67 Suppl. 1: S34-6 (Pubitemid 40721030)
98. Brown AD, Barton DA, Lambert GW. Cardiovascular abnormalities in patients with major depressive disorder autonomic mechanisms and implications for treatment. CNS Drugs 2009; 23: 583-602
99. Vaccarino V, Johnson BD, Sheps DS, et al. Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: The National Heart, Lung, and Blood Institute-sponsored WISE study. J Am Coll Cardiol 2007; 50: 2044-50 (Pubitemid 350087570)
100. Leo R, Di Lorenzo G, Tesauro M, et al. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: Pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry 2006; 67: 1760-6 (Pubitemid 44955158)
101. Lekakis J, Ikonomidis I, Papoutsi Z, et al. Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules. Int J Cardiol 2010; 139: 150-8
102. Sher Y, Lolak S, Maldonado JR. The impact of depression in heart disease. Curr Psychiatry Rep 2010; 12: 255-64
103. MacDonald TM, McMahon AD, Reid IC, et al. Antidepressant drug use in primary care: A record linkage study in Tayside, Scotland. BMJ 1996; 313: 860-1 (Pubitemid 26335212)
104. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: Association with use of tricyclic agents. Am J Med 2000; 108: 2-8 (Pubitemid 30058271)
105. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104: 1894-8 (Pubitemid 32983230)
106. Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol 2001; 52: 179-84 (Pubitemid 32863076)
107. Hippisley-Cox J, Pringle M, Hammersley V, et al. Antidepressants as risk factor for ischaemic heart disease: Casecontrol study in primary care. BMJ 2001; 323: 666-9 (Pubitemid 32897009)
108. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003; 108: 32-6 (Pubitemid 36859016)
109. Schlienger RG, Fischer LM, Jick H, et al. Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf 2004; 27: 1157-65 (Pubitemid 39647855)
110. Monster TB, Johnsen SP, Olsen ML, et al. Antidepressants and risk of first-time hospitalization for myocardial infarction: A population-based case-control study. Am J Med 2004 Nov 15; 117(10): 732-7 (Pubitemid 39482526)
111. Tata LJ, West J, Smith C, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart 2005; 91: 465-71 (Pubitemid 40432771)
112. Barbui C, Percudani M, Fortino I, et al. Past use of selective serotonin reuptake inhibitors and the risk of cerebrovascular events in the elderly. Int Clin Psychopharmacol 2005; 20: 169-71 (Pubitemid 40571516)
113. Chen Y, Guo JJ, Li H, et al. Risk of cerebrovascular events associated with antidepressant use in patients with depression: A population-based, nested case-control study. Ann Pharmacother 2008; 42: 177-84 (Pubitemid 351238564)
114. Trifirò G, Dieleman J, Sen EF, et al. Risk of ischemic stroke associated with antidepressant drug use in elderly persons. J Clin Psychopharmacol 2010; 30: 252-8
115. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006; 63: 1358-67 (Pubitemid 44878519)
116. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry 2003; 54: 227-40 (Pubitemid 37267853)
117. Carney RM, Rich MW, Freedland KE, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988; 50: 627-33 (Pubitemid 19016813)
118. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: A meta-analysis. Psychosom Med 2004; 66: 802-13 (Pubitemid 39552862)
119. van Melle JP, de Jonge P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: Ameta-analysis. Psychosom Med 2004; 66: 814-22 (Pubitemid 39552863)
120. Lesperance F, Frasure-Smith N, Talajic M, et al. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 2002; 105: 1049-53 (Pubitemid 34212612)
121. Bush DE, Ziegelstein RC, Tayback M, et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2001; 88: 337-41 (Pubitemid 32823291)
122. De Jonge P, Honig A, van Melle JP, et al., MIND-IT Investigators. Nonresponse to treatment for depression following myocardial infarction: Association with subsequent cardiac events. Am J Psychiatry 2007; 164: 1371-8 (Pubitemid 47461137)
123. Whooley MA. Depression and cardiovascular disease: Healing the broken-hearted. JAMA 2006; 295: 2874-81 (Pubitemid 43974185)
124. Whooley MA, de Jonge P, Vittinghoff E, et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008; 300: 2379-88
125. Huffman JC, Celano CM, Januzzi JL. The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes. Neuropsychiatr Dis Treat 2010; 6: 123-36
126. Brondy B. Common genetic factors for depression and cardiovascular disease. Dialogues Clin Neurosci 2007; 9: 19-28
127. Robinson RG. Poststroke depression: Prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 2003; 54: 376-87 (Pubitemid 37267864)
128. Ohira T, Iso H, Satoh S, et al. Prospective study of depressive symptoms and risk of stroke among Japanese. Stroke 2001; 32: 903-8
129. Lyketsos CG, TreismanGJ, Lipsey JR, et al.Does stroke cause depression? J Neuropsychiatry Clin Neurosci 1998; 10: 103-7 (Pubitemid 28135132)
130. Carney RM, Freeland KE. Depression and coronary heart disease: More pieces of the puzzle. Am J Psychiatry 2007; 164: 1307-9 (Pubitemid 47461126)
131. Carney RM, Freeland KE. Does treating depression improve survival after acute coronary syndrome? Br J Psychiatry 2007; 190: 467-8
132. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701-9 (Pubitemid 34848222)
133. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003; 289: 3106-16
134. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005; 62: 792-8 (Pubitemid 41002762)
135. van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry 2007; 190: 460-6 (Pubitemid 46868827)
136. Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297: 367-79 (Pubitemid 46155798)
137. Hansen BH, Hanash JA, Rasmussen A, et al. Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD). Trials 2009; 10: 20
138. Rasmussen A, Lunde M, Poulsen DL, et al. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 2003; 44: 216-21 (Pubitemid 36514728)
139. Robinson RG, Jorge RE, Moser DJ, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: A randomized controlled trial. JAMA 2008; 299: 2391-400 (Pubitemid 351749237)
140. Croom KF, Perry CM, Plosker GL. Mirtazapine: A review of its use in major depression and other psychiatric disorders. CNS Drugs 2009; 23: 427-52
141. Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: A systematic review of randomized trials. Can J Psychiatry 2006; 51: 923-9 (Pubitemid 46354056)
142. Mazza M, Lotrionte M, Biondi-Zoccai G, et al. Selective serotonin reuptake inhibitors provide significant lower rehospitalization rates in patients recovering from acute coronary syndromes: Evidence from a meta-analysis. J Psychopharmacol 2010; 24: 1785-92
143. Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/ endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003; 108: 939-44 (Pubitemid 37048222)
144. Krantz DS, Whittaker KS, Francis JL, et al. Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease: Outcomes from the Women's Ischemia Syndrome Evaluation (WISE) study. Heart 2009; 95: 1901-6
145. Massó González EL, Patrignani P, Tacconelli S, et al. Variability among nonsteroidal anti-inflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010; 62: 1592-601
146. Lichtman JH, Bigger JT, Blumenthal JA, et al. Depression and coronary heart disease: Recommendations for screening referral, and treatment. A Science Advisory From the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Psychiatric Association. Circulation 2008; 118: 1768-75